# A Study of TAK-019 in Healthy Japanese Adults (COVID-19)

> **NCT04712110** · PHASE1,PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 200 (actual)

## Conditions studied

- Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

## Interventions

- **BIOLOGICAL:** TAK-019
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04712110
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-12
- **Primary completion:** 2022-03-28
- **Final completion:** 2022-03-28
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2023-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04712110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04712110, "A Study of TAK-019 in Healthy Japanese Adults (COVID-19)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04712110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*